Bristol Myers Squibb (NYSE:BMY) Stock Rating Raised to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Bristol Myers Squibb (NYSE:BMY) from a hold rating to a strong-buy rating in a research note published on Wednesday morning,Zacks reports. Zacks Research also issued estimates for Bristol Myers Squibb’s Q3 2027 earnings at $1.56 EPS, FY2027 earnings at $6.24 EPS, Q1 2028 earnings at $1.48 EPS, Q2 2028 earnings at $1.38 EPS and FY2028 earnings at $5.23 EPS.

A number of other brokerages also recently weighed in on BMY. TD Cowen started coverage on Bristol Myers Squibb in a report on Wednesday, August 5th. They issued a “buy” rating on the stock. JPMorgan Chase & Co. increased their target price on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an “overweight” rating in a report on Friday, July 31st. Sanford C. Bernstein raised shares of Bristol Myers Squibb from a “market perform” rating to an “outperform” rating in a report on Wednesday, August 5th. Citigroup restated a “neutral” rating and issued a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Finally, Roth Capital initiated coverage on shares of Bristol Myers Squibb in a research note on Wednesday, August 5th. They set a “buy” rating and a $75.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $67.06.

Bristol Myers Squibb Trading Up 0.6%

Shares of NYSE:BMY opened at $61.54 on Wednesday. The company has a market capitalization of $125.71 billion, a P/E ratio of 13.56, a P/E/G ratio of 0.30 and a beta of 0.23. Bristol Myers Squibb has a 1 year low of $42.52 and a 1 year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The business’s 50 day simple moving average is $64.44 and its 200 day simple moving average is $60.15.

Bristol Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The firm had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the company posted $1.46 EPS. The company’s revenue was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, research analysts anticipate that Bristol Myers Squibb will post 6.95 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, November 2nd. Shareholders of record on Friday, October 2nd will be issued a dividend of $0.63 per share. The ex-dividend date is Friday, October 2nd. This represents a $2.52 annualized dividend and a yield of 4.1%. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Insider Activity at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total value of $33,750.00. Following the sale, the senior vice president directly owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This represents a 2.88% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.05% of the company’s stock.

Institutional Trading of Bristol Myers Squibb

A number of institutional investors have recently bought and sold shares of BMY. Lazard Asset Management LLC grew its position in Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock valued at $116,693,000 after acquiring an additional 368,193 shares during the last quarter. Callan Family Office LLC bought a new stake in shares of Bristol Myers Squibb in the 2nd quarter worth approximately $3,575,000. BlackRock Inc. boosted its stake in shares of Bristol Myers Squibb by 5.1% in the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. Asset One Wealth Management LLC purchased a new stake in shares of Bristol Myers Squibb in the 4th quarter valued at $4,075,000. Finally, Motley Fool Asset Management LLC grew its holdings in shares of Bristol Myers Squibb by 30.4% during the 4th quarter. Motley Fool Asset Management LLC now owns 216,468 shares of the biopharmaceutical company’s stock valued at $11,676,000 after purchasing an additional 50,403 shares during the last quarter. Institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Zacks Research modestly raised its earnings forecasts for Bristol Myers Squibb, increasing estimates for third-quarter 2027 EPS to $1.56, full-year 2027 EPS to $6.24, first- and second-quarter 2028 EPS to $1.48 and $1.38, respectively, and full-year 2028 EPS to $5.23 from $5.17. The revisions suggest slightly improved expectations for the company’s future earnings. Zacks Research estimates
• Positive Sentiment: BMY was added to Zacks’ Rank #1 Strong Buy list and its Strong Buy income-stock list. The ratings may support demand for the shares, particularly because Bristol Myers Squibb offers significant cash flow and an attractive dividend profile. Zacks Strong Buy list
• Positive Sentiment: The company selected Onco360 as a restricted specialty-pharmacy provider for ZENBEXUS (iberdomide), its newly approved multiple-myeloma treatment. The distribution arrangement and clinical support could help the drug reach eligible patients during its commercial rollout. ZENBEXUS pharmacy network
• Positive Sentiment: Bristol Myers Squibb completed a Phase 1 lung-cancer combination study, providing incremental support for its immuno-oncology pipeline. Analysts also highlighted newer medicines as increasingly important in offsetting declines from mature products. Lung cancer study update
• Negative Sentiment: Despite the near-term positives, investors remain concerned about patent expirations and declines in established blockbuster products. Longer-term Zacks estimates remain below current-year expectations, underscoring the need for newer drugs such as ZENBEXUS to replace lost revenue.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its portfolio includes therapies for cancer, blood disorders, cardiovascular disease, immune-mediated conditions and psychiatric disorders. Key products include Opdivo and Yervoy for oncology, Eliquis for reducing the risk of stroke and systemic embolism, Revlimid for certain blood cancers, and several other specialty medicines.

The company serves patients and healthcare providers in markets around the world, with operations and commercial activities spanning North America, Europe, Asia-Pacific and other international regions.